Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125397 | 0.80 | BDKRB1 (0.55) | MCOLN3HSD11B1NR1H4KMT2ABDKRB1 | |
| SCHEMBL4027618 | 0.80 | MCOLN3 (0.54) | MCOLN3HSD11B1KMT2AITGAVCCR4 | |
| SCHEMBL5111767 | 0.76 | NR3C1 (0.38) | MCOLN3HSD11B1NR1H4KMT2AITGAV | |
| SCHEMBL6184837 | 0.73 | MCOLN3 (0.56) | MCOLN3HSD11B1NR1H4BDKRB1ITGAV | |
| SCHEMBL5125439 | 0.73 | BDKRB1 (0.52) | KMT2ABDKRB1ALDH1A1 | |
| SCHEMBL4036166 | 0.73 | HTT (0.49) | MCOLN3HSD11B1NR1H4ITGAVHTT | |
| SCHEMBL5117999 | 0.72 | BDKRB1 (0.42) | MCOLN3HSD11B1NR1H4KMT2ABDKRB1 | |
| SCHEMBL3439979 | 0.72 | MCOLN3 (0.55) | MCOLN3HSD11B1KMT2ABDKRB1ITGAV | |
| SCHEMBL5111158 | 0.70 | MCOLN3 (0.52) | MCOLN3HSD11B1KMT2ABDKRB1HTT | |
| SCHEMBL2642338 | 0.70 | MCOLN3 (0.67) | MCOLN3HSD11B1KMT2ACCR4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | MCOLN3 4434/4885HSD11B1 521/4885NR1H4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.